To reassess the prognostic value of minimal residual disease(MRD)and IKZF1 gene deletions in adults with B-cell acute lymphoblastic leukemia(B-ALL)who received pediatric-specific chemotherapy regimens during the Nanfang Hospital PDT-ALL-2016 trial. The gene discussed is IKZF1; the disease is acute lymphoblastic leukemia.